Mass Spectrometry for Drug Target Discovery
The Kessler group has expertise in ubiquitin biology, deubiquitylases DUBs, mass spectrometry and proteomics.
Mass Spectrometry is key technology for studying critical molecules and pathways. Defining molecular targets is crucial for the process of drug development. In our group, we are focused on using proteomics, mass spectrometry and biochemical approaches to understand disease processes.
Kessler Group Lab Retreat Limassol Cyprus May 2022
The Kessler group has expertise in proteomics based methodologies and hosts a platform containing a variety of chromatography equipment and mass spectrometers. We apply mass spectrometry to discover "molecular windows" of human diseases to accelerate target discovery.
The group consists of multiple teams:
- Ubiquitin Protease Biology Team (Kessler Lab TDI)
- Discovery Proteomics Facility
- Metabolomics & Lipidomics Teams
- Single Cell & Spatial Proteomics Group (Roman Fischer)
- Structural & Mechanistic Proteomics Facility (Darragh O'Brien)